|
Sep 24
|
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
|
|
Jul 30
|
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
|
|
Jun 24
|
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
|
|
Apr 18
|
Panbela Announces Poster Presentation at American Association for Cancer Research:
|
|
Apr 16
|
Panbela Announces Transfer to OTCQB Market
|
|
Dec 21
|
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
|
|
Dec 18
|
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
|
|
Dec 4
|
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
|
|
Nov 29
|
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
|
|
Sep 5
|
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
|
|
Jul 10
|
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
|
|
Apr 24
|
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
|